1887
  1. الرئيسية
  2. A-Z Publications
  3. QScience Connect
  4. المجلد 2014, العدد 1
  5. المقالة
Volume 2014, Issue 1
  • E-ISSN: 2223-506X

ملخص

Most cases of chronic myeloid leukemia (CML) are associated with the presence of fusion gene; a molecular anomaly that introduced targeting therapy to CML. This study was setup primarily to optimize the real-time quantification detection of transcripts, in order to pave the way for using this method as a diagnostic tool to support the clinical management of CML patients in Qatar.

A secondary objective was to evaluate the response of CML patients to Imatinib (IM) and exploit adaption of this technique as an indicator of emerging drug resistance reported in Qatar.

Peripheral blood (PB) samples from 26 CML patients receiving Imatinib, were analysed via serial Real-time quantitative polymerase chain reaction (RT-qPCR) to monitor the ratio of to normal transcripts. EuropeanLeukemia Net (ELN) 2006 and 2009 guidelines were employed to assess the molecular response to Imatinib.

For patients to be classified as optimal responders, major molecular response (MMR) had to be achieved by 18 months of treatment.1 Patients responding to Imatinib achieved major molecular response (MMR) during the 1st year of treatment; while patients who resisted Imatinib treatment did not achieve any molecular response within this time frame.

This was the first molecular study to evaluate the molecular response of CML patients (citizens and residents) to IM in Qatar.

© 2014 Al-Dewik, Jewell, Yassin, El-Ayoubi, Morsi, licensee Bloomsbury Qatar Foundation Journals.
Loading

جارٍ تحميل قياسات المقالة...

/content/journals/10.5339/connect.2014.24
٢٠١٤-١١-٠١
٢٠٢٤-٠٥-١٩
Loading full text...

Full text loading...

/deliver/fulltext/connect/2014/1/connect.2014.24.html?itemId=/content/journals/10.5339/connect.2014.24&mimeType=html&fmt=ahah

References

  1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985; 315:6020:550–554.
     [Google الباحث العلمي]
  2. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007; 249:2:121–132.
     [Google الباحث العلمي]
  3. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996; 88:7:2375–2384.
     [Google الباحث العلمي]
  4. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006; 125::69–92.
     [Google الباحث العلمي]
  5. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009; 22:3:355–365.
     [Google الباحث العلمي]
  6. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwhohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederweiser D, Silver R, Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108:6:1809–1820.
     [Google الباحث العلمي]
  7. Baccarani M, Cortes J, Pane F, Niederweiser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwhohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver R, Goldman J, Hehlmann R. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27:35:6041–6051.
     [Google الباحث العلمي]
  8. Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J, Cervantes F, Clark R, Cortes J, Guilhot F, Hjorth-Hansen H, Hughes T, Kantarjian H, Kim DW, Larson R, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederweiser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman J, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122:6:872–884.
     [Google الباحث العلمي]
  9. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JLE, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJM. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003; 17:12:2318–2357.
     [Google الباحث العلمي]
  10. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman J, Radich JP. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349:15:1423–1432.
     [Google الباحث العلمي]
  11. Bustin SA. Developments in real-time PCR research and molecular diagnostics. Expert Rev Mol Diagn. 2010;  10:6:713–715.
     [Google الباحث العلمي]
  12. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NCP, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108:1:28–37.
     [Google الباحث العلمي]
  13. Branford S, Fletcher L, Cross NCP, Müller MC, Hochhaus A, Kim DW, Radich J, Saglio G, Pane F, Kamel-Reid S, Lynn Wang Y, Press RD, Lynch K, Rudzki Z, Goldman J, Hughes T. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112:8:3330–3338.
     [Google الباحث العلمي]
  14. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Bradford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ESK, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman J, Matcalfe P, Cross NCP. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010; 116:22:e111–e117.
     [Google الباحث العلمي]
  15. Branford S, Cross NCP, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J, Hughes T. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006; 20:11:1925–1930.
     [Google الباحث العلمي]
  16. Beillard E, Pallisgaard N, van der Velden VHJ, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJM, Hokland P, Gabert J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia. 2003; 17:12:2474–2486.
     [Google الباحث العلمي]
  17. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med. 2006; 125::93–106.
     [Google الباحث العلمي]
  18. Gerrard G, Mudge K, Stewart R, Foskett P, Stevens D, Khorashad JS, Szdio R, Rezvani K, Marin D, Reid A, Apperley J, Goldman J, Foroni L. Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies. Am J Hematol. 2011; 86:3:313–315.
     [Google الباحث العلمي]
  19. Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, Gonzalez de Castro D, Austin S, Awan A, Burt E, Clench T, Farruggia J, Hancock J, Irvine AE, Kizilors A, Langabeer S, Milner BJ, Nickless G, Schuh A, Sproul A, Wang L, Wickham C, Cross NCP. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol. 2011; 153:2:179–190.
     [Google الباحث العلمي]
  20. Al-Dewik NI, Jewell AP, Yassin MM, El-Ayoubi HR, Morsi HM. Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. Adv Appl Biomed. 2013; 2013::1. 10.5339/aabio.2013.1.
     [Google الباحث العلمي]
  21. McNiven M, Talaulikar D. Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay. Pathology. 2012; 44:1:55–57.
     [Google الباحث العلمي]
  22. de Lavallade H, Apperley J, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman J, Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26:20:3358–3363.
     [Google الباحث العلمي]
  23. Khalil SH, Abu-Amero KK, Mohared FA, Chaudhri NA. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: Experience at a tertiary care hospital in Saudi Arabia. Genet Test Mol Biomarkers. 2010; 14:1:67–74.
     [Google الباحث العلمي]
  24. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: Results with four tyrosine kinase inhibitor modalities. Blood. 2013; 121:24:4867–4874.
     [Google الباحث العلمي]
  25. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clar RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman J, Foroni L. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30:3:232–238.
     [Google الباحث العلمي]
  26. Kim D, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol. 2014; 89:6:626–632.
     [Google الباحث العلمي]
http://instance.metastore.ingenta.com/content/journals/10.5339/connect.2014.24
Loading
Molecular Monitoring of patients with Chronic Myeloid Leukemia (CML) in the state of Qatar: Optimization of Techniques and Response to Imatinib
QScience Connect 2014, 24 (٢٠١٤); https://doi.org/10.5339/connect.2014.24
/content/journals/10.5339/connect.2014.24
/content/journals/10.5339/connect.2014.24
Loading

جارٍ تحميل البيانات والوسائط...

  • نوع المستند: Research Article
الموضوعات الرئيسية ABL1, BCR-ABL1, CML, Imatinib Mesylate (IM) and RT-qPCR

الأكثر اقتباسًا لهذا الشهر Most Cited RSS feed

هذه الخانة مطلوبة
يُرجى إدخال عنوان بريد إلكتروني صالح
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error